Status:

UNKNOWN

Effect of Viscous Soluble Fibres on Body Weight

Lead Sponsor:

Unity Health Toronto

Conditions:

Overweight and Obesity

T2DM (Type 2 Diabetes Mellitus)

Eligibility:

All Genders

Brief Summary

Abstract: Background: Obesity is a global pandemic affects all age groups and is independent risk factors for most chronic diseases. Dietary intervention is an essential component of obesity manageme...

Detailed Description

Background: Obesity is a global pandemic and is an independent risk factor for chronic disease. Dietary intervention is an essential component of obesity management. Observational studies show an inve...

Eligibility Criteria

Inclusion

  • Must be a randomized controlled clinical trial with either a parallel or cross-over design
  • Must have a treatment period of at least 4 week.
  • Healthy children and adults, overweight and obese individuals or individuals with diabetes were all acceptable
  • Must have one of the selected viscous fibres, (agar, alginate, β-glucan, guar gum, pectin, polyglycoplex(PGX), Psyllium, Xanthan), as a supplemented treatment.
  • Only β-glucan sources from barley or oat were accepted The amount of barley product or barley β-glucan must be reported or measured, or must be computable. β-glucan was considered to be 4.75% in barley, and 3-5% in oat.
  • Must be appropriately controlled.
  • Must measure one of outcomes: body weight, BMI, waist circumference, or Body fat percentage.
  • These Anthropometry measures can be either primary or secondary outcomes.
  • Enough information must be provided to calculate the magnitude of effect, i.e. end of treatment measures and/or change from baseline measures
  • Ad lipitum diet only.

Exclusion

  • If the soluble fibre was not one of the selected viscous fibre or a combination.
  • supplement where these fibers could not be isolated each one alone.
  • If the study was insufficiently controlled, i.e. the control was another soluble fibre.
  • If the outcome measures did not include body weight, BMI, waist circumference, or Body fat percentage.
  • If the intervention was a diet with no supplemented fibre.
  • If the study provided insufficient information to calculate a magnitude of effect
  • If the study protocol maintains baseline weight.
  • Secondary information such as reviews, editorials, commentaries, were excluded
  • If the diet is hypo-caloric, energy restricted diet, or metabolically controlled diet.

Key Trial Info

Start Date :

March 1 2016

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

November 1 2017

Estimated Enrollment :

1268 Patients enrolled

Trial Details

Trial ID

NCT03257449

Start Date

March 1 2016

End Date

November 1 2017

Last Update

August 22 2017

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

The Toronto 3D Knowledge Synthesis and Clinical Trials Unit, Clinical Nutrition and Risk Factor Modification Centre

Toronto, Ontario, Canada, M5C 2T2